Chinese eye disease specialist Arctic Vision Biotechnology Co. Ltd. raised more than $100 million in a series B financing round. The clinical-stage company will use the funds to initiate a phase III trial for its core asset, ARVN-001 (triamcinolone acetonide suprachoroidal injectable suspension), for uveitic macular edema in China this year.
DUBLIN – Agomab Therapeutics NV raised $74 million in a series B round that attracted two heavyweight U.S. crossover investors, Redmile Group, which led the financing, and Cormorant Asset Management.
Four years after leaving the Nasdaq, Sciclone Pharmaceuticals Holdings Ltd. returned to the market March 3, issuing 116 million shares to raise HK$2.18 billion (US$281 million) on the Hong Kong Stock Exchange (HKEX). Shares were priced at HK$18.8 each.
LONDON – Neophore Ltd. announced the close of a $21 million series B that will enable it to further advance a portfolio of small-molecule DNA mismatch repair (MMR) inhibitors over the next 2.5 years.
TORONTO – Novel. Unique. Revolutionary. Terms too often used to indiscriminately describe medical devices that have yet to prove their stuff. Not so at France’s Ministry of Health which takes care to deem winning devices under its Forfait Innovation (FI) program “truly innovative, not simply incremental developments.” Last week the FI awarded Vancouver, British Columbia’s Evasc Neurovascular Inc. €2.76 million (US$3.37 million) to test its CE-marked Eclips for treating intracranial bifurcation aneurysms during a 119-patient trial at 20 French sites in 2021.
RSS
